192 related articles for article (PubMed ID: 35362262)
1. Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer.
Zhang C; Chong X; Jiang F; Gao J; Chen Y; Jia K; Fan M; Liu X; An J; Li J; Zhang X; Shen L
J Extracell Vesicles; 2022 Apr; 11(4):e12209. PubMed ID: 35362262
[TBL] [Abstract][Full Text] [Related]
2. Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy.
Jiang F; Zhang Z; Chong X; Shen L; Fan M; Liu X; An J; Peng Z; Zhang C
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077704
[TBL] [Abstract][Full Text] [Related]
3. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors.
Brocco D; Lanuti P; Pieragostino D; Cufaro MC; Simeone P; Bologna G; Di Marino P; De Tursi M; Grassadonia A; Irtelli L; De Lellis L; Veschi S; Florio R; Federici L; Marchisio M; Miscia S; Cama A; Tinari N; Del Boccio P
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546102
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of the Immune Cell Infiltration Landscape in Gastric Cancer to Assistant Immunotherapy.
Li C; Pan J; Jiang Y; Yu Y; Jin Z; Chen X
Front Genet; 2021; 12():793628. PubMed ID: 35069691
[No Abstract] [Full Text] [Related]
6. Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer.
Wang JB; Qiu QZ; Zheng QL; Zhao YJ; Xu Y; Zhang T; Wang SH; Wang Q; Jin QW; Ye YH; Li P; Xie JW; Lin JX; Lu J; Chen QY; Cao LL; Yang YH; Zheng CH; Huang CM
Adv Sci (Weinh); 2023 May; 10(15):e2207417. PubMed ID: 36998102
[TBL] [Abstract][Full Text] [Related]
7. EV PD-L1 Contributes to Immunosuppressive CD8
Zhang X; Liu Z; Hou Y; Jiao H; Ren J; Wang G
Technol Cancer Res Treat; 2021; 20():15330338211041264. PubMed ID: 34519584
[TBL] [Abstract][Full Text] [Related]
8. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
9. miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer.
Zhang C; Yang J; Chen Y; Jiang F; Liao H; Liu X; Wang Y; Kong G; Zhang X; Li J; Gao J; Shen L
Gastric Cancer; 2022 Mar; 25(2):360-374. PubMed ID: 35031872
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic strategy in the management of gastric cancer: molecular profiles, current practice, and ongoing trials.
Lu M; Wu Y; Zhang Y; Yu Y; Wang S; Su X
J Egypt Natl Canc Inst; 2023 Oct; 35(1):32. PubMed ID: 37779128
[TBL] [Abstract][Full Text] [Related]
11. uPAR
Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
[TBL] [Abstract][Full Text] [Related]
12. Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome.
Shi A; Kasumova GG; Michaud WA; Cintolo-Gonzalez J; Díaz-Martínez M; Ohmura J; Mehta A; Chien I; Frederick DT; Cohen S; Plana D; Johnson D; Flaherty KT; Sullivan RJ; Kellis M; Boland GM
Sci Adv; 2020 Nov; 6(46):. PubMed ID: 33188016
[TBL] [Abstract][Full Text] [Related]
13. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
[TBL] [Abstract][Full Text] [Related]
14. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
[TBL] [Abstract][Full Text] [Related]
15. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies.
Zhang C; Chen Z; Chong X; Chen Y; Wang Z; Yu R; Sun T; Chen X; Shao Y; Zhang X; Gao J; Shen L
Clin Transl Med; 2020 Dec; 10(8):e254. PubMed ID: 33377634
[TBL] [Abstract][Full Text] [Related]
17. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
18. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
19. A new risk model based on a 11-m
Lei L; Li N; Yuan P; Liu D
BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
[TBL] [Abstract][Full Text] [Related]
20. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
Front Oncol; 2021; 11():658690. PubMed ID: 34150625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
